Identification of the Metabolic Signature of Atrial Fibrillation for Personalized Prevention
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: FA ablation, Lab test.
- Who it may be relevant to
- Registry conditions: Atrial Fibrillation (AF). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Atrial fibrillation (AF) is a major public health problem. The efficacy of the existing techniques is limited in the more aggressive forms. It is therefore necessary to develop approaches, in particular the identification of relevant biomarkers, to prevent the onset, recurrence or progression of AF in at-risk patients. The objective of this study is to describe the longitudinal metabolic and biomolecular signature of AF in patients eligible for cardiac ablation.
Detailed description
Atrial fibrillation (AF) is a major public health problem. Its prevalence exceeds 2%. The main aim of drug treatment is to prevent the onset of stroke and heart failure, but side effects often require discontinuation, and contraindications limit their use. Rhythm control strategies based on catheter ablation have led to significant progress in incident AF, improving quality of life. Nevertheless, the efficacy of these techniques is limited in the more aggressive forms. Significant recurrence rates are reported one year after ablation, and access to them is often reserved for symptomatic patients due to their invasive and costly nature.
It is therefore necessary to develop approaches to prevent the onset, recurrence or progression of AF in at-risk patients. While the pathophysiology of AF involves metabolic remodelling that can be observed in animal and human models, no clinically relevant metabolites have been identified as biomarkers of the risk of AF onset or progression, with a view to preventive and personalized management.
In response to this unmet need, this project aims to develop a method for assessing the risk of AF recurrence, combining the identification of a metabolic signature of the arrhythmia and the patient, with a machine learning approach to aggregate conventional risk factors and metabolic biomarkers. A longitudinal clinical study will be conducted on patients scheduled for AF ablation, to monitor changes in their metabolic signature over 12 months, in parallel with arrhythmia progression. Using machine learning, the study team will establish and validate a classifier retrospectively stratifying patients with or without recurrent AF, and compare this method with canonical risk stratification. This will enable to consider personalized management of patients at risk of recurrence, with the aim of reducing human and economic costs.
Interventions
- Procedure FA ablation
Ablation of the FA - Biological Lab test
Blood collection
Primary outcome measures
- Biomarkers T1 [Time frame: Day 0]
- Biomarkers T2 [Time frame: Day 1]
- Biomarkers 2 [Time frame: 12 months]
Secondary outcome measures (2)
- Algorithm [Time frame: Month 12]
- Atrial electroanatomy and apneas [Time frame: Immediately after the procedure]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years, all genders, and ethnic origins
- Free, informed, and written consent signed
- Person affiliated to or benefiting from a social security scheme
Exclusion criteria
- Age < 18 years
- Lack of informed consent
- Gestating women (pregnancy test carried out as part of care for FA patients, contraception, or menopause for women in control groups)
- Persons under administrative or judicial protection
- Endocarditis or pericarditis in progress or within the 3 last months
- Active tumor pathology (benign or malignant)
- Chronic inflammation or autoimmune disease
- Chronic liver disease
- Myocardial infarction within the last 8 weeks
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Non-randomized
- Model
- Sequential
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
France · 1 center
- University Hospital of Bordeaux — Pessac
Identifiers
NCT: NCT06735001 · CHUBX 2024/01 · 2024-A00416-41